Paul Negulescu, SVP and disease area executive for Vertex's pain program

Q&A: Ver­tex’s pain re­search chief on mov­ing be­yond opi­oids, AI and how phar­ma ac­qui­si­tions thrive or fail

SAN DIEGO — For savvy deal­mak­ing, Ver­tex’s 2001 ac­qui­si­tion of Au­ro­ra Bio­sciences is near the top of the list.

Ver­tex bought the San Diego biotech for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.